Efficacy and safety of a switch to latanoprost 0.005% + timolol maleate 0.5% fixed combination eyedrops from tafluprost 0.0015% monotherapy.

Efficacy and safety of a switch to latanoprost 0.005% + timolol maleate 0.5% fixed combination eyedrops from tafluprost 0.0015% monotherapy. - Efficacy and safety of a switch to latanoprost 0.005% + timolol maleate 0.5% fixed combination eyedrops from tafluprost 0.0015% monotherapy.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017687

Enrollment

Registered

2015-05-26

Start date

2013-12-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

glaucoma

Interventions

Switch to latanoprost/timolol fixed combination from tafluprost monotherapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: # Inadequate intraocular pressure reduction in tafulprost monotherapy # Primary open angle glaucoma

Exclusion criteria

Exclusion criteria: # Angle closure # History of glaucoma surgery # Bronchial asthma

Design outcomes

Primary

Measure	Time frame
intraocuar pressure	—

Secondary

Measure	Time frame
complications	—

Countries

Japan

Contacts

Public ContactDaisuke Shiba

Keio university school of medicine Department of ophthalmology

shiba@personal.email.ne.jp03-3353-1211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026